Genomic Testing in Lung Cancer: Tools, Timing, and Clinical Impact

This opening segment introduces the goals of the OncLive Insights program and frames genomic testing as a core element of the modern lung cancer diagnostic pathway.

This segment focuses on how clinicians decide between tissue biopsy and blood based testing when planning initial genomic evaluation.

This segment focuses on how clinicians decide between tissue biopsy and blood based testing when planning initial genomic evaluation. Dr Singhal describes how patient factors such as tumor location, disease burden, and the feasibility of obtaining a tissue sample guide this decision.

This segment examines how comprehensive genomic profiling is now being used earlier in the lung cancer disease course.